trending Market Intelligence /marketintelligence/en/news-insights/trending/cqvXuvsEsXW2Py1GXVEopw2 content esgSubNav
In This List

Takeda begins US government-backed phase 1 trial for Zika vaccine

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Takeda begins US government-backed phase 1 trial for Zika vaccine

Takeda Pharmaceutical Co. Ltd. has started a phase 1 clinical trial, which is backed by the U.S. government, for its Zika virus vaccine TAK-426.

SNL Image

The Japanese drugmaker, which is working on vaccines for two of the world's most prevalent mosquito-borne viruses, was awarded funding from the Department of Health and Human Services to develop the Zika vaccine in September 2016.

The trial will evaluate safety and immunogenicity of TAK-426 in subjects between the ages of 18 and 49 in the continental U.S. and U.S. territories, and will be conducted under a U.S. investigational new drug application.

Initial data from the trial is expected in 2018, and Takeda plans to start working toward initiating phase 2 studies as soon as possible.